Diasome Pharmaceuticals, Inc. Announces Notice of Allowance from US PTO for Liver Targeting System for Insulin

Share Article

Hepatic targeted insulin technology designed to make approved insulin therapies safer and more effective

The HDV cell targeting system provides advanced nanotechnology to current insulin therapies.

Diasome Pharmaceuticals, Inc. (http://www.diasome.com) has received notice from its licensor, SDG, Inc., that a United States patent has recently been allowed for the Company’s technology for liver-targeted insulin therapy.

Entitled “Lipid Construct for Delivery of Insulin to a Mammal,” this patent covers composition of matter claims related to the use of Diasome’s proprietary Hepatocyte Directed Vesicles (“HDV”) as a system for enabling injected insulin to more effectively reach the liver’s metabolic cells, called hepatocytes.

“While all naturally secreted insulin is first and primarily used by the liver as a signal to store sugar from the food we eat, injected insulin therapy has been shown to have great difficulty in successfully reaching the liver in patients with diabetes,” said W. Blair Geho, MD, PhD, Diasome’s Chief Scientific Officer. “The HDV system has been designed as a potentially first-in-class additive to approved insulin therapies and has been shown in Phase 2 human testing to have a significant and positive impact on controlling blood sugar levels in patients.”

Diasome’s most advanced clinical-stage therapy is an injected form of pre-meal insulin that incorporates the HDV nanotechnology system. This product has been enabled for Phase 3 testing by the US FDA.

About Diasome Pharmaceuticals, Inc.

Diasome Pharmaceuticals, Inc. is focused on the clinical and commercial development of breakthrough therapies for diabetes and obesity. Based on more than thirty years of research and development in the fields of cell receptor targeting, insulin replacement, and hepatic (liver) glucose metabolism, the Company’s pipeline includes multiple injected and oral formulations of liver targeted insulins for both Type 1 and Type 2 diabetic patients that are Phase 3 ready. In addition, Diasome is developing a first-in-class oral compound for the Type 2 diabetes population that is based upon new insights into normal glucose metabolism and a novel mechanism of action, along with a nanotechnology-based oral compound that may have a significant impact in treating obesity.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Robert Geho
Visit website